/PRNewswire/ -- Human papillomavirus (HPV) causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers. Thanks to research being done at Tufts University School of Medicine, patients infected with cancer-causing HPV may someday have an alternative to surgical and harsh chemical treatments. In a study funded by the National Institutes of Health and published online in advance of print in The FASEB Journal, the researchers report on the development of a protein-based inhibitor that could provide a topical treatment for HPV.
"Currently, there is no cure for HPV, and the available treatment options involve destroying the affected tissue. We have developed a protein inhibitor that blocks HPV protein expression in cell culture, a first step toward a topically-applied treatment for this cancer-causing virus," said senior author James Baleja, Ph.D., associate professor of biochemistry at Tufts University School of Medicine (TUSM) and member of the biochemistry program faculty at the Sackler School of Graduate Biomedical Sciences at Tufts.
"Vaccines are helping to lower the incidence of HPV, but vaccines will not help the millions of women and men who currently have an infection, especially those who have high-risk and persistent infections. Social and economic challenges make widespread administration of a vaccine difficult, particularly in developing countries. A topical treatment for HPV could provide an economical option," he continued.
HPV affects approximately 20 million people in the United States, making it the most common sexually transmitted infection. There are more than 100 types of HPV of which more than 40 are sexually transmitted. These include two high-risk types, HPV-16 and HPV-18, which cause the majority of cervical and anogenital cancers, and some portion of head and neck cancers, particularly oral cavity and oropharynx cancers. Cervical cancer is diagnosed in nearly 500,000 women each year, killing 250,000 annually. In the United States, it was estimated that 12,000 women in 2010 would be diagnosed with cervical cancer, while 10,100 women and men in the United States get vulvar, vaginal, penile or anal cancers each year. In addition, some portion of the head and neck cancers in the United States (11,300 men and women each year) is attributable to HPV. Other types of HPV, or low-risk HPV, can cause genital warts or are infections that clear on their own.
In their efforts to inhibit HPV, Baleja and his team zeroed in on the viral protein E2, which controls viral activities including DNA replication and the activation of cancer-causing genes. Using structure-guided design, the team developed a protein called E2R that prevents E2 from functioning normally. When the researchers applied E2R to a cell model of HPV biology, viral gene transcription was halted. Because HPV infects epithelial cells, the outermost layer of the skin and the mucous membranes, protein inhibitors such as E2R could be applied in a topical form.
Baleja and colleagues used biophysical tools including circular dichroism spectroscopy and x-ray crystallography to test the structure and stability of different inhibitors. The most stable inhibitor was then tested in mammalian cells and was found to inhibit the E2 protein of HPV-16, the high-risk strain that is most commonly associated with cancers. The data in this study suggest that the inhibitor may also be effective against another high-risk virus, HPV-18, as well as a low-risk virus, HPV-6a, which causes warts.
Additional authors on the paper are first author Kakoli Bose, Ph.D., formerly a postdoctoral fellow in the Baleja laboratory at TUSM and now with the Advanced Centre for Treatment, Research and Education in Cancer at the Tata Memorial Center in India; Gretchen Meinke, Ph.D., senior research associate in the Bohm Laboratory at TUSM, and Andrew Bohm, associate professor in the Department of Biochemistry at TUSM and member of the biochemistry program faculty at the Sackler School of Graduate Biomedical Sciences.
This research was funded by the National Cancer Institute, part of the National Institutes of Health, and by the Lifespan/Tufts/Brown Center for AIDS Research (CFAR), a joint research effort between Tufts and Brown Universities and their affiliated hospitals and centers. CFAR is funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Bose K, Meinke G, Bohm A, and Baleja J. The FASEB Journal. "Design and characterization of an enhanced repressor of human papillomavirus E2 protein." Published online April 11, 2011. DOI 10.1096/fj.10-176461
-----
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG @FayetteFP
Friday, April 29, 2011
Protein Inhibitor May Bring a Topical Treatment for HPV
Posted by
Georgia Front Page.com
at
10:02 AM
0
comments
Labels: cancer, cervical, fayette front page, flu vaccine, georgia, georgia front page, HPV, inhibitor, protein, research, treatment, tufts
Wednesday, December 23, 2009
FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older
/PRNewswire/ -- The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.
People in this age group are at highest risk for seasonal influenza complications, which may result in hospitalization and death. Annual vaccination remains the best protection from influenza, particularly for people 65 and older.
Fluzone High-Dose was approved via the accelerated approval pathway. FDA's accelerated approval pathway helps safe and effective medical products for serious or life-threatening diseases become available sooner. In clinical studies, Fluzone High-Dose demonstrated an enhanced immune response compared with Fluzone in individuals 65 and older.
As part of the accelerated approval process, the manufacturer is required to conduct further studies to verify that the Fluzone High-Dose will decrease seasonal influenza disease after vaccination.
"As people grow older, their immune systems typically become weaker," said Karen Midthun, M.D., acting director of the FDA's Center for Biologics Evaluation and Research. "This is the first influenza vaccine that uses a higher dose to induce a stronger immune response that is intended to better protect the elderly against seasonal influenza."
Fluzone High-Dose, manufactured by Sanofi Pasteur Inc., is formulated so that each 0.5 mL dose contains a total of 180 micrograms (mcg) of influenza virus hemagglutinin (HA) which is made up of 60 mcg of each of the three influenza virus strains.
Other currently licensed seasonal influenza vaccines for adults are formulated to contain a total of 45 mcg of influenza virus hemagglutinin (15 mcg HA from each of the three influenza strains per dose). Sanofi Pasteur, also manufactures Fluzone, a seasonal vaccine for the United States approved for use in individuals ages 6 months and older.
As expected, because of the higher HA content, non-serious adverse events were more frequent after vaccination with Fluzone High-Dose compared with Fluzone. Common adverse events experienced during clinical studies included pain, redness and swelling at the injection site and headache, muscle aches, fever and malaise. The rate of serious adverse events was comparable between Fluzone High-Dose and Fluzone.
People with hypersensitivity to egg proteins or life-threatening reactions after previous administration of any influenza vaccine should not be vaccinated with Fluzone High-Dose.
Fluzone High-Dose is administered as a single injection in the upper arm and is available in single dose pre-filled syringes without preservative.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
7:18 PM
0
comments
Labels: approval, fayette, fayette front page, fda, flu vaccine, fluzone, georgia, georgia front page, high dose, influenza, seniors
Monday, November 30, 2009
FDA Approves Agriflu Seasonal Influenza Vaccine
The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.
Agriflu, manufactured by Novartis Vaccines and Diagnostics in Siena, Italy, was approved using the FDA’s accelerated approval pathway, which helps safe and effective medical products for serious or life-threatening diseases become available sooner. In this case, Novartis demonstrated that the vaccine induced levels of antibodies in the blood likely to be effective in preventing seasonal influenza.
Agriflu is administered as a single injection in the upper arm and is available in single dose, pre-filled syringes that do not contain preservatives.
“The approval of the new seasonal influenza vaccine, Agriflu, is an important step in adding to the production capacity to enhance the supply of vaccine for the United States for future influenza seasons,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.
Common side effects in clinical studies included pain, swelling and redness at the injection site, headache, muscle aches and malaise. People with severe or life-threatening allergies to chicken eggs, or to any other substance in the vaccine, should not be vaccinated.
As part of the accelerated approval process, Novartis is required to conduct further studies to verify that the vaccine induces levels of antibodies in the blood that are effective in preventing seasonal influenza. The company also manufactures another licensed seasonal influenza vaccine, Fluvirin, for use in the United States. Fluvirinis approved for people ages 4 years and older. Agriflu is not intended to protect against the 2009 H1N1 influenza.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
9:39 AM
0
comments
Labels: agriflu, approval, fayette, fayette front page, fda, flu vaccine, georgia, georgia front page, influenza, vaccine, virus
Monday, November 16, 2009
FDA Approves Additional Vaccine for 2009 H1N1 Influenza Virus
The U.S. Food and Drug Administration announced that it has approved a fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC.
As with the four previous H1N1 influenza vaccines licensed by the FDA on Sept.15, 2009, ID Biomedical Corporation will manufacture its H1N1 vaccine using the established, licensed egg-based manufacturing process used for producing seasonal flu vaccine.
Potential side effects of this H1N1 vaccine are expected to be similar to those of the seasonal and H1N1 flu vaccines. The most common side effect is soreness at the injection site. Others may include mild fever, body aches and fatigue for a few days after the inoculation.
As with any medical product, unexpected or rare serious adverse events may occur. The FDA is collaborating with other government agencies to enhance adverse event safety monitoring during and after the H1N1 2009 vaccination program.
ID Biomedical’s H1N1 monovalent vaccine will be produced in multi-dose vials, in a formulation that contains thimerosal.
As with any medical product, unexpected or rare serious adverse events may occur. FDA is collaborating with the U.S. Department of Health and Human Services, including the Centers for Disease Control and Prevention, and other government agencies to enhance the capacity for adverse event safety monitoring during and after the 2009 H1N1 vaccination program.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
3:24 PM
0
comments
Labels: approval, fayette, fayette front page, fda, flu vaccine, georgia, georgia front page, H1N1, vaccine
FDA Expands Use of CSL Limited’s Seasonal and H1N1 Vaccines to Infants and Children
The U.S. Food and Drug Administration has approved the use of the CSL Limited’s seasonal and 2009 H1N1 influenza vaccines to include children ages 6 months and older. These vaccine were previously approved for use in adults, ages 18 years and older
“Because children are among those most vulnerable to the 2009 H1N1 virus, having a broader range of vaccines available for use in children is an important step in responding to the H1N1 outbreak,” said Margaret A. Hamburg, M.D., commissioner of food and drugs.
The company’s 2009 H1N1 vaccine is manufactured and tested using the same well-established licensing processes that have been in place for many years for the company’s seasonal flu vaccine.
The approval was based on a study of the company’s seasonal flu vaccine in children, showing both the vaccine's safety and its ability to induce antibodies expected to protect against influenza. These findings supported approval under FDA's accelerated approval regulations, which help safe and effective medical products for serious or life-threatening diseases to become available sooner to the public.
Common adverse events experienced by children after administration of seasonal and H1N1 vaccines typically include pain, redness and swelling at the injection site as well as, in some cases, irritability, loss of appetite and drowsiness.
As with any medical product, unexpected or rare serious adverse events may occur. FDA is collaborating with the U.S. Department of Health and Human Services, including the Centers for Disease Control and Prevention, and other government agencies to enhance the capacity for adverse event safety monitoring during and after the 2009 H1N1 vaccination program.
Because CSL’s seasonal and H1N1 monovalent vaccines contain a small amount of egg protein, they should not be administered to anyone allergic to eggs or egg products.
The vaccines will be available both in single-dose, preservative-free, pre-filled syringes and in multi-dose vials that contain thimerosal, a mercury derivative, as a preservative.
Both vaccines are manufactured by CSL Ltd. of Australia.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
12:50 PM
0
comments
Labels: approval, children, fayette, fayette front page, fda, flu, flu vaccine, georgia, georgia front page, H1N1, seasonal, vaccine
Friday, September 11, 2009
Statement by Dr. Anthony Fauci, NIH Regarding Early Results from Clinical Trials of 2009 H1N1 Influenza Vaccines in Healthy Adults
Statement by Dr. Anthony Fauci
Director, National Institute of Allergy and Infections Diseases, NIH
Regarding Early Results from Clinical Trials of 2009 H1N1 Influenza
Vaccines in Healthy Adults
We are encouraged by reports that are now emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers. We expect additional companies to announce their preliminary trial results shortly. The early data from these trials
indicate that 2009 H1N1 influenza vaccines are well tolerated and induce a strong immune response in most healthy adults when administered in a single unadjuvanted 15-microgram dose. We congratulate the companies on these trials, which are an important part of the ongoing worldwide effort to develop vaccines to protect the public from 2009 H1N1 influenza.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, also is conducting clinical trials of 2009 H1N1 influenza vaccines, produced by Sanofi Pasteur and CSL Limited. The NIAID trials are testing two different dosages (15 micrograms versus 30 micrograms) and evaluating the immune response to one and two doses of these vaccines. More than 2,800 people are participating in ongoing NIAID trials of these vaccines.
We are pleased to note that preliminary analyses of early data from the NIAID trials align with the recently announced findings and those to be announced imminently by other companies in that both vaccines studied induced what is likely to be a protective immune response in most adults following a single dose in the same amount (15 micrograms) used in seasonal flu vaccines. Specifically, in blood samples obtained 8 to 10 days after vaccination:
* Among healthy adults who received a single 15-microgram dose of
the Sanofi Pasteur vaccine, a robust immune response was measured in 96
percent of adults aged 18 to 64 and in 56 percent of adults aged 65 and
older.
* Similarly, among healthy adults who received a single
15-microgram dose of the CSL Limited vaccine, a robust immune response
was measured in 80 percent of adults aged 18 to 64 and in 60 percent of
adults aged 65 and older.
Additional data from the NIAID trials are forthcoming. However, on the basis of these strong early data, our results are consonant with other reports that a single 15-microgram dose of unadjuvanted 2009 H1N1 influenza vaccine is well tolerated and induces a robust immune response in healthy adults between the ages of 18 and 64. For adults aged 65 and over, the immune response to 2009 H1N1 influenza vaccine is somewhat less robust, as is the case with seasonal influenza vaccines.
We note that the slight discrepancies seen in our trials between the Sanofi Pasteur and CSL Limited vaccines may be due to technical differences in the preliminary measurement of the amounts of antigen in the doses used in the clinical trial lots and the relatively limited numbers of samples studied to date, as well as the fact that our data are drawn from a very early time point after immunization.
NIAID will continue to provide timely updates on these trials as well as those in children and in pregnant women, which began later.
Information from the NIAID studies will help inform the development of recommendations for immunization schedules, including the optimal dosage and number of doses for different age groups.
NIAID is conducting these clinical trials through its longstanding vaccine clinical trials infrastructure: the Vaccine and Treatment Evaluation Units, a network of medical centers that offers rapid response capability to test vaccines for emerging public health concerns. Detailed information is available from the NIAID Web site (www.niaid.nih.gov) and from http://ClinicalTrials.gov.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
3:02 PM
0
comments
Labels: atlanta, clinical trials, fayette front page, flu vaccine, georgia, georgia front page, H1N1, H1N1 vaccine, influenza, NIH, report, results, vaccine
Thursday, August 20, 2009
Accelerated Approval of Hiberix to Help Sustain Adequate Vaccine Supply
The U.S. Food and Drug Administration today approved Hiberix, a Haemophilus influenzae Type b (Hib) vaccine, as a booster dose for children 15 months through 4 years old. Hiberix is manufactured by GlaxoSmithKline, with U.S. headquarters in Research Triangle Park, N.C. and Philadelphia.
A nationwide shortage of Hib vaccine began in December 2007 due to a voluntary recall by the manufacturer and subsequent production suspension of PedvaxHIB and COMVAX, two of four vaccines licensed in the United States for primary and booster immunization against invasive disease due to Hib. Both PedvaxHIB and COMVAX vaccines are manufactured by Merck & Co. Inc. (Whitehouse Station, N.J.).
This shortage resulted in a recommendation by the U.S. Centers for Disease Control and Prevention to temporarily defer the Hib vaccine booster dose for children who were not at high risk for infection, until the vaccine supply could be restored. This deferral was in effect from Dec. 18, 2007, through June 25, 2009.
Although current vaccine supply is sufficient to reinstate the booster dose and begin catch-up vaccination, it is not yet ample enough to support mass vaccination of all children whose boosters were deferred.
“The FDA approved Hiberix under the agency’s accelerated approval pathway,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research. “This approval will provide an additional safe and effective vaccine to help ensure that there is an adequate Hib vaccine supply during necessary catch-up vaccinations.”
Before the availability of Hib vaccines, Hib disease was the leading cause of bacterial meningitis among children under 5 years old in the United States. Meningitis is an infection of the tissue covering the brain and spinal cord, which can lead to lasting brain damage and deafness. Hib disease can also cause pneumonia, severe swelling in the throat, infections of the blood, joints, bones, and tissue covering of the heart, as well as death. Hib disease is spread through the air by coughing and sneezing.
In 1992, the FDA disseminated rules regarding accelerated approval. The rules allow for earlier approval of treatments that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (including products that provide prophylaxis to those who would not otherwise be treated during a shortage). The use of such an approach can shorten the time required for product testing prior to receiving FDA approval. Accelerated approval is granted on the condition that clinical trials are continued during the post-approval marketing of the product to verify the anticipated clinical benefit.
Hiberix is used in nearly 100 countries. The FDA based its conclusion that Hiberix is safe and effective for use as a booster dose in certain children in the United States on data from seven clinical studies conducted in Europe, Latin America and Canada that involved more than 1,000 children.
As part of the approval, the manufacturer, GlaxoSmithKline, will conduct a post-market study in the United States to evaluate the safety and immunogenicity of primary and booster vaccination with Hiberix compared to a Hib vaccine already licensed in the United States. The study is intended to confirm the clinical benefit of booster immunization with Hiberix in accordance with the accelerated approval regulations, and to provide additional data on Hiberix for young infants.
The most common side effects seen in the studies following a booster dose of Hiberix included pain and redness at the injection site, fever, fussiness, loss of appetite and restlessness.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
6:45 AM
0
comments
Labels: atlanta, booster, children, fayette front page, fda. hiberix, flu vaccine, georgia, georgia front page, haemophilis, Hib, shortage
Monday, July 20, 2009
FDA Approves Vaccine for 2009-2010 Seasonal Influenza
The U.S. Food and Drug Administration today announced that it has approved a vaccine for 2009-2010 seasonal influenza in the United States.
The seasonal influenza vaccine will not protect against the 2009 H1N1 influenza virus that resulted in the declaration of a pandemic by the World Health Organization (WHO) on June 11, 2009. The FDA continues to work with manufacturers, international partners and other government agencies to facilitate the availability of a safe and effective vaccine against the 2009 H1N1 influenza virus.
Although this year’s seasonal vaccine is directed against other strains of influenza expected to be circulating and will not provide protection against the 2009 H1N1 influenza virus, it is still important for those Americans for whom it is recommended to receive the seasonal influenza vaccine. No vaccine is 100 percent effective against preventing disease, but vaccination is the best protection against influenza and can prevent many illnesses and deaths.
“The approval of this year’s seasonal influenza vaccine is an example of the FDA’s important responsibility to assure timely availability of vaccine to help protect the health of the American public,” said Margaret A. Hamburg, M.D., commissioner of food and drugs. “A new seasonal influenza vaccine each year is a critical tool in protecting public health.”
The six vaccine brand names and manufacturers are: Afluria, CSL Limited; Fluarix, GlaxoSmithKline Biologicals; FluLaval, ID Biomedical Corporation; Fluvirin, Novartis Vaccines and Diagnostics Limited; Fluzone, Sanofi Pasteur Inc.; and FluMist, MedImmune Vaccines Inc.
Each year, experts from the FDA, WHO, U.S. Centers for Disease Control and Prevention (CDC), and other institutions study virus samples and patterns collected from around the world in an effort to identify strains that may cause the most illness in the upcoming season.
Based on those forecasts and on the recommendations of the FDA’s Vaccine and Related Products Advisory Committee, the FDA determines the three strains that manufacturers should include in their vaccines for the U.S. population. The closer the match between the circulating strains and the strains in the vaccine, the better the protection against the disease.
The vaccine for the 2009-2010 seasonal influenza contains:
* an A/Brisbane/59/2007 (H1N1)-like virus
* an A/Brisbane/10/2007 (H3N2)-like virus
* a B/Brisbane/60/2008-like virus
There is always a possibility of a less than optimal match between the virus strains predicted to circulate and the virus strains that end up causing the most illness. Even if the vaccine and the circulating strains are not an exact match, the vaccine may reduce the severity of the illness or may help prevent influenza-related complications.
According to the CDC, between 5 percent and 20 percent of the U.S. population develops influenza each year. More than 200,000 are hospitalized from its complications and about 36,000 people die. Older people, young children, and people with chronic medical conditions are at higher risk for influenza-related complications. Vaccination of these groups is critical.
Additionally, influenza immunization of health care personnel is important in protecting them and others from influenza.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
4:51 PM
0
comments
Labels: 2009, approval, atlanta, fayette front page, fda, flu vaccine, georgia, georgia front page, seasonal flu
Wednesday, May 6, 2009
FDA Approves New Influenza Vaccine Production Facility
The U.S. Food and Drug Administration (FDA) today announced that it has approved a new manufacturing facility used to produce influenza virus vaccines. The facility is approved for seasonal influenza vaccine production and could be used for the production of vaccine against the new 2009 H1N1 influenza strain.
As part of its overall pandemic influenza preparedness efforts, the FDA meets with vaccine manufacturers to guide the efficient establishment of influenza vaccine facilities that comply with agency requirements. The agency promptly reviews applications and manufacturing supplements that could increase both the number of manufacturers and the overall supply of vaccine.
The facility, located in the United States, is owned and operated by sanofi pasteur, which manufactures Fluzone Influenza Virus Vaccine. This new facility will greatly increase sanofi pasteur’s production capability.
“This approval represents an important step towards increasing the availability of influenza vaccines,” said Karen Midthun, M.D., the FDA’s acting director of the Center for Biologics Evaluation and Research.
“Increased manufacturing capacity for influenza vaccine is critical to our preparedness for an influenza pandemic,” said Jesse Goodman, M.D., M.P.H., the FDA’s acting chief scientist and deputy commissioner for scientific and medical programs. “This action also enhances the ability to produce and provide vaccines to protect the public from seasonal influenza, still estimated to cause more than 30,000 deaths per year. Thanks to strategic investments by the federal government and proactive efforts and engagement by the FDA and the vaccine industry, our nation’s preparedness has come a long way over the last five years.”
The FDA has interacted with the company throughout the regulatory process to help ensure compliance with applicable requirements.
The bulk manufacturing facility will be used for the production of Fluzone, sanofi pasteur’s egg-based influenza vaccine.
Sanofi Pasteur is located in Swiftwater, Pa.
-----
Community News You Can Use
Follow on Twitter @GAFrontPage
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
5:22 PM
0
comments
Labels: atlanta, fayette front page, fda, flu vaccine, fluzone, georgia, georgia front page, H1N1, manufacturing, swine flu virus, vaccine
Wednesday, April 29, 2009
Flu Vaccine Given in Microneedle Patches Proves Effective in Mice
Flu vaccine delivered through skin patches containing microneedles has proven just as effective at preventing influenza in mice as intramuscular, hypodermic flu immunization. A team of researchers at Emory University and the Georgia Institute of Technology believes the new microneedle skin patch method of delivering flu vaccine could improve overall seasonal vaccination coverage in people because of decreased pain, increased convenience, lower cost and simpler logistics over conventional hypodermic immunization.
The research was published in the early online edition of the journal Proceedings of the National Academy of Sciences (PNAS). Another study by the research team on a different influenza strain was described in the journal Public Library of Science (PLoS) One.
The patches used in the experiments contained an array of stainless steel microneedles coated with inactivated influenza virus. The patches were pressed manually into the skin and after a few minutes, the vaccine coating dissolved off within the skin. The coated microneedle immunizations were compared to conventional intramuscular hypodermic injections at the same dose in another group of mice.
The researchers found that the microneedle vaccinations induced strong immune responses against influenza virus that were comparable to immune responses induced by the intramuscular, hypodermic immunizations. One month after vaccination, the researchers infected both groups of mice with a high dose of influenza virus. While all mice in a control group of unvaccinated mice died of influenza, all mice in both the hypodermic and the microneedle groups survived.
“Our findings show that microneedle patches are just as effective at protecting against influenza as conventional hypodermic immunizations,” says Richard Compans, PhD, Emory professor of microbiology and immunology and one of the paper’s senior authors. “In addition, vaccine delivery into the skin is desirable because of the skin’s rich immune network.”
Even though cutaneous immunization has been shown to induce a broad range of immune responses, and to be especially effective in individuals over age 60, this method has not been widely used because it has not been convenient and has required highly trained personnel.
"Unlike conventional hypodermic injections, microneedles are prepared in a patch for simple administration, possibly by patients themselves, and inserted painlessly onto the skin without specialized training,” says Mark Prausnitz, PhD, professor in the Georgia Tech School of Chemical and Biomolecular Engineering and co-senior author. “These micron-scale needles can be mass produced using low-cost methods for distribution to doctors’ offices, pharmacies and, possibly, people’s homes.”
Other advantages of the microneedle patches could include more convenient storage, easier transportation and lower dosage requirements. Lower doses could be particularly important because flu vaccine production capacity sometimes is limited for seasonal vaccine, and a future influenza pandemic would require much greater production of vaccine.
Replacing a hypodermic needle with a microneedle patch also could significantly impact the way other vaccines are delivered, and could be particularly beneficial in developing countries. A microneedle patch could fit inside an envelope for delivery by the postal service and would occupy much less storage space. Patches also would increase vaccine safety by reducing the dangers of accidental or intentional hypodermic needle re-use.
The project team plans future immunization studies in other animal models, including guinea pigs or ferrets, before initiating studies in humans. Also, more studies are needed to determine the minimum vaccine dose needed for full protection.
The Emory and Georgia Tech research team began developing the new microneedle vaccine patch technology in 2007 using grants from the National Institutes of Health (NIH). The project team has extensive experience in microneedle development, influenza vaccines, vaccine delivery systems, product development and interdisciplinary collaboration.
In 2007 the NIH awarded a $32.8 million, seven-year contract to Emory, along with the University of Georgia, to establish the Emory/UGA Influenza Pathogenesis and Immunology Research Center. The center is working to improve the effectiveness of flu vaccines through a number of different projects studying how influenza viruses attack their hosts, how they are transmitted, and what new immune targets might be identified for antiviral medicines.
Prausnitz and his colleagues have been working since the mid 1990s to develop microneedle technology for painless drug and vaccine delivery through the skin. The Georgia Tech team has also developed manufacturing processes for microneedle patches and tested the ability of the needles to deliver proteins, vaccines, nanoparticles, and other small and large molecules through the skin.
Other authors of the papers are Emory microbiologists Ioanna Skountzou and Chinglai Yang, and first authors Ling Ye, Qiyun Zhu, Dimitrios Koutsonanos, and Maria del Pilar Martin from Emory and Vladimir Zarnitsyn from Georgia Tech. Other authors and contributors were Yulong Gao, Lei Pan, and Zhiyuan Wen from Emory, and Harvinder Gill and Sean Sullivan from Georgia Tech.
-----
Community News You Can Use
www.fayettefrontpage.com
www.georgiafrontpage.com
Twitter @GAFrontPage
Posted by
Georgia Front Page.com
at
9:28 AM
0
comments
Labels: atlanta, emory university, fayette front page, flu vaccine, georgia, georgia front page, georgia tech, microneedle, painless, skin patch
Tuesday, December 9, 2008
Families Fighting Flu and CDC Encourage Parents to Vaccinate Kids Against Flu
/PRNewswire-USNewswire/ -- Families Fighting Flu, Inc. (FFF), together with the Centers for Disease Control and Prevention (CDC) are designating today, December 9, the second annual Children's Flu Vaccination Day to remind parents that it's not too late to get their children vaccinated against influenza, or "the flu." The day highlights the critical need for all children aged six months through 18 years to get vaccinated against the flu. According to the CDC, vaccination is the single best means of protecting children from the flu and preventing the spread of influenza, which can lead to hospitalization and even death. Children's Flu Vaccination Day occurs during the CDC's annual National Influenza Vaccination Week (December 8-14, 2008).
"There is a misconception that after Thanksgiving it's too late to get children vaccinated against the flu. That is one of the reasons why we have designated today as Children's Flu Vaccination Day - to remind parents that it's not too late to get their children vaccinated. In fact, flu activity typically does not reach its peak until January or February, and it can occur as late as May," said Anne Schuchat, M.D. Assistant Surgeon General and Director, National Center for Immunization and Respiratory Diseases at the CDC.
Children die every year in the United States from influenza and its complications. In fact, over the past five flu seasons more than 400 children have died from influenza, and more than 20,000 children under the age of five are hospitalized due to influenza each year. Only 22 percent of children six to 23 months of age were fully vaccinated against influenza during the 2007-2008 flu season, even though the CDC recommends that all of these children get vaccinated every year.
But, it's not just kids who need to get immunized. Parents should also get vaccinated against the flu to better protect their family and loved ones from spreading the disease. A new national FFF survey of mothers of children in child care revealed that 56 percent of mothers said they have not received an influenza vaccination for themselves within the past two years.
"We know that come December many parents, unfortunately, think that flu season has already passed. But the reality is it hasn't even started in some areas of the country and is just starting in others. Our hope is that by designating today as Children's Flu Vaccination Day we will help remind parents that their children are still susceptible to getting the flu, and that the best way to help protect their family is to get themselves and their children vaccinated as soon as possible," said Julie Moise, FFF board member. Moise's 6-and-1/2-month-old son, Ian, died suddenly in December 2003 from influenza.
FFF has created a new e-card that's available at www.familiesfightingflu.org designed to be distributed starting today and throughout the rest of flu vaccination season (March 2009) to parents to remind them to get their children vaccinated against the flu. Contact your healthcare provider or local health department to find out when and where to get a flu vaccine.
Who Should Get Vaccinated?
The CDC recommends that all children aged six months through 18 years get vaccinated against the flu every year, as well as all persons who want to reduce the risk of becoming ill with the flu or transmitting it to others. This includes (but is not limited to): children with certain medical conditions; household contacts (parents, siblings, grandparents, etc.) and caregivers of children less than five years old; and household contacts of other high-risk individuals.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
9:42 AM
0
comments
Labels: atlanta, cdc, children, families, fayette, fayette front page, fayetteville, flu, flu vaccine, georgia, georgia front page, peachtree city, tyrone, vaccinated
Thursday, October 9, 2008
Nation's Teen Vaccination Coverage Increasing, But Below 2010 Goals
The nation's immunization coverage rates for preteens and teens are increasing for routinely recommended vaccines, but most still do not have all of the recommended immunizations, according to 2007 estimates released today by the Centers for Disease Control and Prevention (CDC).
"The overall trends are good news," said Dr. Lance Rodewald, director of the Division of Immunization Services at the CDC's National Center for Immunization and Respiratory Diseases. "We are seeing more preteens and teenagers being protected against serious, sometimes deadly diseases. But we remain short of our goals -- for almost all of these vaccines we want at least 90 percent of adolescents to be fully immunized. As such, we have much work to do to get many more adolescents protected."
The survey provides estimates for three vaccines recommended at 11 or 12 years of age: the tetanus-diphtheria-acellular pertussis (Tdap) vaccine, the meningococcal conjugate vaccine (MCV4), and the human papillomavirus (HPV4) vaccine for girls and young women. It also includes estimates of the percentage of 13- through 17-year-old teens who should have received the recommended immunizations for measles, mumps and rubella vaccine (MMR), hepatitis B (HepB) vaccine, and varicella vaccine (VAR) earlier in life.
According to Rodewald, the nation's Healthy People 2010 goals for preteens and teens ages 13-15 years are not being met for any of the vaccines for which goals were set. The Healthy People 2010 goals are for 90 percent coverage for preteens and teens 13 to 15 years of age with three doses of hepatitis B vaccine, two doses of measles, mumps and rubella vaccine, one dose of either tetanus-diphtheria or tetanus, diphtheria and acellular pertussis vaccine, and one dose of varicella vaccine for those who have not previously had chickenpox. There is not a Healthy People 2010 goal for HPV vaccination, which was first licensed and recommended in 2006.
The survey found that, compared to 2006, there was a substantial increase in the percentage of preteens and teens who had received the recommended vaccinations. Specific findings included:
-- Vaccination coverage levels for three or more doses of hepatitis B
(HepB) and two or more doses of measles, mumps and rubella vaccine
(MMR) were over 80 percent;
-- Coverage with one dose of varicella vaccine (VAR) was high at 75.7
percent but coverage with two doses was low at 18.8 percent among
preteens and teens without a previous history of disease;
-- 32.4 percent of preteens and teens surveyed had received MCV4
vaccination, up from 11.7 percent in 2006 (a 20.7 percentage point
increase);
-- 30.4 percent had received Tdap vaccination, up from 10.8 percent in
2006 (a 19.6 percentage point increase);
-- 25.1 percent of adolescent females had received at least one dose of
HPV vaccine
Rodewald encourages parents to take their preteens and teenagers for routine medical checkups as a way to ensure they receive the recommended vaccinations.
Additional Background Information
The meningococcal conjugate vaccine (MCV4) vaccine protects against meningococcal meningitis, the tetanus-diphtheria-acellular pertussis (Tdap) vaccine protects against pertussis, also known as whooping cough, and the human papillomavirus (HPV) vaccine protects girls against cervical cancer. The recommended series consists of one dose of Tdap vaccine, one dose of the MCV4 vaccine, and three doses of the HPV4 vaccine.
CDC has conducted the National Immunization Survey for teens since 2006. It is similar to the standard NIS which began in 1994, that collects immunization information among children 19 through 35 months old. It is a random digit-dialed telephone survey.
-----
www.georgiafrontpage.com
Georgia Front Page
www.fayettefrontpage.com
Fayette Front Page
Posted by
Georgia Front Page.com
at
6:58 PM
0
comments
Labels: atlanta, cdc, cervial cancer, fayette, fayette front page, fayetteville, flu vaccine, georgia, georgia front page, girls, HPV, immunization, peachtree city, preteens, teenage, tyrone
Friday, October 3, 2008
Maxim Health Systems Launches Georgia Flu Vaccination Program
PRNewswire/ -- Maxim Health Systems launched its influenza vaccination program on October 1 across the state of Georgia, after recent debates within the state over whether flu shots would be available to patients outside of Physicians' offices.
In early September, the Georgia State Board of Pharmacy and the Composite State Board of Medical Examiners issued statements that the influenza vaccine is a "dangerous drug" and therefore requires a patient-specific prescription. This classification called into question the legality of nurses administering the flu vaccine without a patient specific script.
Dedicated to making the flu vaccine available at convenient locations for Georgia residents, Maxim contacted its retained counsel, Robert Highsmith and Paul Vranicar of Holland & Knight LLP. Highsmith and Vranicar worked with Georgia Governor Sonny Perdue and the Division of Public Health (DPH) of the Department of Human Resources to enter into an agency agreement with Maxim to invoke a provision of Georgia law allowing nurses who are agents of the DPH to order and dispense "dangerous drugs" under nurse protocols. In essence, this agreement permits Maxim nurses to continue administering flu shots in Georgia without patient-specific prescriptions.
The Governor also issued a public statement calling on "healthcare professionals [to] act in the best interests of public health and continue prior practices" concerning the administration of flu shots. As a result of the Governor's decisive action and the cooperation of the Division of Public Health, Maxim customers will not experience any impact on the quality of services they have come to expect or the quantity of flu shots available this flu season.
Maxim has partnered with local Georgia retail stores, a list of which can be found at http://www.findaflushot.com/, as part of a national campaign to offer immunizations at more than 25,000 retail locations across the U.S. The program aims to increase the number of people who get vaccinated, a step determined by the Centers for Disease Control and Prevention (CDC) as the single most effective way to prevent flu. Maxim's Web site, http://www.findaflushot.com/, helps users quickly locate nearby vaccination sites by simply entering their zip code. This will provide users with the address, driving directions, dates, and times for flu shots at local clinics. The Web site also provides the latest news on influenza and links to other resources to learn more about the flu and prevention strategies.
Each year as many as 65 million Americans fall victim to influenza and flu-related complications, such as pneumonia. This results in approximately 200,000 hospitalizations and 36,000 deaths, which is more than the number of Americans who die each year from breast cancer, and two to three times as many as those who die from HIV/AIDS.(1) Everyone is encouraged to get vaccinated, especially individuals considered to be at higher risk. The CDC defines those with an increased risk of developing influenza-related complications as:
-- Children aged 6 months -- 18 years old
-- Pregnant women
-- People 50 years of age and older
-- People of any age with certain chronic medical conditions
-- People who live in nursing homes and other long term care facilities
"We believe that everyone who can, should get a flu shot and we especially encourage those in high-risk categories along with their family members to get vaccinated," says Steve Pellito, National Director of Maxim Health Systems.
For those who prefer to find a convenient location over the phone, Maxim provides a toll free number at 877-962-9358. Maxim also offers clinics to corporations, senior living facilities, schools, and Physicians' offices to help create ease of access and ensure those at highest risk of contracting the flu have ample resources available to obtain a vaccination.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
1:56 PM
0
comments
Labels: atlanta, fayette, fayette county, fayette front page, flu vaccine, georgia, georgia front page, influenza, nurse, peachtree city, prescription, sonny perdue, tyrone
Thursday, September 25, 2008
Most Parents Are Unaware of Expanded CDC Flu Vaccination Recommendations
PRNewswire-USNewswire/ -- Only one in 10 parents is aware of the recommended age range for children to be vaccinated against the flu, according to a new survey. The Centers for Disease Control and Prevention (CDC) expanded the flu vaccination recommendations in February 2008 to include all children from 6 months through 18 years old, expanding vaccinations to 30 million more school-age children.
The survey also found that during the past two years, nearly 60 percent of parents did not get their children vaccinated against the flu. To drive awareness of the new recommendations and the importance of flu vaccinations, Families Fighting Flu (FFF) -- a group of parents who have lost a child to the flu -- the Visiting Nurse Associations of America (VNAA) -- the largest non-profit network of flu immunizers -- and The Clorox Company have teamed up to help educate families about the broadened recommendations and to increase the number of people getting flu vaccinations nationwide through the Say "Boo!" to the Flu program.
"My wife and I didn't realize how important one flu vaccination could be until we lost our daughter, Amanda, to the flu," said Richard Kanowitz, President of FFF. "That is why this program is so important to us -- Say 'Boo!' to the Flu educates parents on the importance of getting their kids vaccinated and other steps they can take to help prevent the spread of the flu virus."
In its third year, the Say "Boo!" to the Flu program educates families nationwide on how to treat the entire family to a healthier, happier flu season. The program features a bus tour that will travel across the country, stopping along the way to vaccinate families in 12 cities and give them the tricks they need to fight the flu virus this flu season.
"It's crucial that parents stay informed and make it a priority to vaccinate their families against the flu every year," said Mary Ann Blade, a VNAA representative. "Say 'Boo!' to the Flu brings flu prevention to the whole family, since the CDC says that household contacts and caregivers -- moms, dads, grandparents, nannies and other child care providers -- should also get vaccinated."
Everyone is Saying "Boo!" to the Flu!
The Say "Boo!" to the Flu bus tour will kick off September 27 in Atlanta, bringing flu vaccinations and simple prevention tips to families across the country throughout the month of October, before flu activity peaks. Halloween games and giveaways like stickers, t-shirts and Clorox Disinfecting Wipes are part of every event.
In addition to the traveling Say "Boo!" to the Flu tour, other groups will be signing on to help say "boo!" to the flu, too. Visiting Nurse Associations across the country, pediatricians' offices, flu shot clinics, child care centers and moms' groups nationwide will receive Say "Boo!" to the Flu materials, resources and tools to help prevent the spread of the flu virus in their communities.
Visit www.SayBooToTheFlu.com for the complete tour schedule, downloadable family activities, a flu clinic locator and simple flu prevention tips.
News for Parents
The survey, conducted by the Say "Boo!" to the Flu program partners, also found:
Parents need to brush up on their flu facts.
-- Only 10 percent of parents knew that the CDC recommends the flu
vaccination for children from 6 months through 18 years.
-- Ninety percent of parents did not know that a child can be contagious
for more than seven days after becoming sick.
-- Flu vaccinations are not a top priority on parents' winter to-do
lists.
-- When parents think about fall and winter woes, most name the high cost
of heating fuel as their biggest dread this coming season. Only 15
percent said they most dread the possibility of a family member
catching the flu.
-- A majority of parents (52 percent) are only slightly or not at all
concerned that their child or children will catch the flu within the
next six months.
-- Nearly 60 percent (57 percent) of parents have NOT gotten their
children vaccinated against the flu in the past two years.
-- Most parents who don't get their children vaccinated against the
flu say they don't think the vaccine is necessary (29 percent).
-- Among parents who have not taken their children to get a flu shot
within the past two years, 58 percent said they would be likely to
do it if they could get the flu shot at locations such as schools,
shopping malls, grocery stores or public parks.
You Can Scare Away the Flu, Too!
Aside from getting vaccinated against the flu, there are other simple steps families can take to help prevent the spread of the flu virus -- and other potentially harmful bacteria and viruses -- in their homes:
-- Wash Hands Frequently: Wash hands with warm water and soap for at
least 20 seconds (the time it takes to sing the "Happy Birthday" song
twice).
-- Disinfect Germ Hot Spots: Kids can touch up to 300 surfaces in 30
minutes, so disinfect the surfaces kids touch most frequently -- like
doorknobs, light switches, faucets or plastic toys.
-- Do the Elbow Cough: Cough and sneeze into your elbow instead of your
hands to help prevent the spread of germs from touch.
-- Follow Good Health Guidelines: Eat right, exercise, and get plenty of
sleep to help boost your body's ability to fight the effects of colds
and the flu.
-----
www.georgiafrontpage.com
Georgia Front Page
www.fayettefrontpage.com
Fayette Front Page
Posted by
Georgia Front Page.com
at
6:48 AM
0
comments
Labels: atlanta, cdc, fayette, fayette county, fayette front page, flu, flu vaccine, georgia, georgia front page, influenza, peachtree city
Tuesday, August 5, 2008
FDA Approves 2008-2009 Flu Vaccines
The U.S. Food and Drug Administration (FDA) today announced that it has approved this year's seasonal influenza vaccines that include new strains of the virus likely to cause flu in the United States during the 2008-2009 season.
The six vaccines and their manufacturers are: CSL Limited, Afluria; GlaxoSmithKline Biologicals, Fluarix; ID Biomedical Corporation of Quebec, FluLaval; MedImmune Vaccines Inc., FluMist; Novartis Vaccines and Diagnostics Limited, Fluvirin; and Sanofi Pasteur Inc., Fluzone.
Approval information and specific indications can be found at http://www.fda.gov/cber/flu/flu2008.htm.
This season's vaccines contain three strains of the influenza virus that disease experts expect to be the most likely cause of the flu in the United States.
Each season's vaccines are modified to reflect the virus strains most likely to be circulating. The closer the match between the circulating strains and the strains in the vaccines, the better the protection.
There is always a possibility of a less than optimal match between the virus strains predicted to circulate and what virus strains end up causing the most illness. Even if the vaccines and the circulating strains are not an exact match, they will provide some protection and may reduce the severity of the illness or prevent flu-related complications.
"One of the biggest challenges in the fight against influenza is producing new vaccines every year," said Jesse L. Goodman, M.D., M.P.H., director of FDA's Center for Biologics Evaluation and Research. "There is no other instance where new vaccines must be made every year. The approval of flu vaccines is a part of FDA's mission to promote the health of Americans throughout the year."
The FDA changed all three strains for this year's influenza vaccine—an unusual occurrence, as usually only one or two strains are updated from year to year. A list of the strains included in the 2008-2009 vaccine can be found at http://www.fda.gov/cber/flu/flu2008.htm. Of note, two of the three strains recommended for the U.S. this year are now in use for the Southern Hemisphere's 2008 influenza season, which is currently underway.
Each year, experts from the FDA, World Health Organization, U.S. Centers for Disease Control and Prevention (CDC), and other institutions study virus samples and patterns collected throughout the year from around the world in an effort to identify strains that may cause the most illness in the upcoming season.
Based on those forecasts and on the recommendations of its Advisory Committee, the FDA each February decides on the three strains that manufacturers should include in their vaccines for the U.S. population. The FDA makes this decision early in the year so that manufacturers have enough time to produce the new vaccines.
Vaccination remains the cornerstone of preventing influenza, a contagious respiratory illness caused by influenza viruses. According to the CDC, every year an average of 5 to 20 percent of the U.S. population gets the flu, more than 200,000 are hospitalized from flu complications and there are about 36,000 flu-related deaths. Some individuals—the elderly, young children, and people with chronic medical conditions —are at higher risk for flu-related complications. Vaccination of these groups and of health care personnel is critical.
"Currently, only 40 percent of health care workers in the United States are vaccinated against influenza," said Department of Health and Human Services' Assistant Secretary of Health Joxel Garcia, M.D., M.B.A.
"Increasing the number of vaccinated health care personnel can be a strong front in the annual battle against the flu," said Garcia. "Health care workers can set an example for the patients they serve as well as decrease the likelihood of contracting and transmitting the virus."
-----
www.georgiafrontpage.com
Georgia Front Page
www.fayettefrontpage.com
Fayette Front Page
Posted by
Georgia Front Page.com
at
9:02 PM
0
comments
Labels: cdc, fayette, fayette county, fayette front page, fayetteville, fda, flu vaccine, georgia front page, influenza, newnan, peachtree city, strains, tyrone, vaccination